What is the appropriate starting dose of insulin degludec (Tresiba) for a patient weighing 155.8 lb with an A1c of 12.2%?

Tresiba Starting Dose

For this patient weighing 155.8 lbs (70.7 kg) with an A1c of 12.2%, start Tresiba at 10 units once daily if insulin-naïve, or use weight-based dosing of 7-14 units once daily (0.1-0.2 units/kg). 1

Dosing Rationale

Type 2 Diabetes (Most Likely Scenario)

Given the A1c of 12.2%, this patient requires basal insulin initiation. The FDA label for Tresiba provides clear guidance:

• Standard starting dose: 10 units once daily for insulin-naïve patients with type 2 diabetes 1
• Weight-based alternative: 0.1-0.2 units/kg per day 2
  • At 70.7 kg: This equals 7-14 units daily
  • The 10-unit fixed dose falls appropriately within this range

If Type 1 Diabetes

If this patient has type 1 diabetes (less likely given the A1c presentation), the approach differs:

• Calculate total daily insulin: 0.2-0.4 units/kg = 14-28 units total daily dose 1
• Tresiba dose = one-third to one-half of total = 5-14 units once daily
• Remainder given as rapid-acting insulin with meals

Titration Protocol

Increase by 2 units every 3-4 days to reach fasting plasma glucose goal without hypoglycemia 2, 1. The 2025 ADA Standards of Care explicitly recommend this evidence-based titration algorithm for basal insulin analogs.

Key Titration Points:

• Monitor fasting blood glucose closely
• Set individualized FPG target (typically 80-130 mg/dL)
• If hypoglycemia occurs without clear cause, reduce dose by 10-20% 2
• Reassess every 3-6 months to avoid therapeutic inertia 2

Critical Considerations for This High A1c

With an A1c of 12.2%, the 2025 ADA guidelines note that insulin may be considered as first injectable therapy when A1c >10% 2. This patient's severely elevated A1c warrants:

• Aggressive glucose monitoring during initiation and titration
• Consider symptoms of hyperglycemia (polyuria, polydipsia, weight loss)
• Rule out type 1 diabetes if clinical presentation suggests it
• May need combination therapy with GLP-1 RA if not already prescribed 2

Administration Details

• Timing: Once daily at any time of day for adults (flexibility is a Tresiba advantage) 1
• Injection sites: Rotate between thigh, upper arm, or abdomen 1
• Formulation choice: Either U-100 or U-200 FlexTouch pen (no dose conversion needed) 1
• Minimum interval: If dose missed, ensure at least 8 hours between injections 1

Safety Monitoring

Prescribe glucagon for emergent hypoglycemia as recommended by ADA guidelines 2. With this elevated A1c, the initial hypoglycemia risk is lower, but increases as glucose normalizes during titration.

Common Pitfalls to Avoid:

• Do NOT mix or dilute Tresiba with other insulins 1
• Do NOT transfer from pen to syringe 1
• Do NOT use intravenously or in insulin pumps 1
• Rotate injection sites to prevent lipodystrophy, which can cause erratic absorption 1

The real-world data from Chinese hospitalized patients showed initial IDeg doses of 0.15-0.18 units/kg/day were often inadequate 3, supporting the FDA's recommendation to start at the higher end (0.2 units/kg or 10 units fixed dose) and titrate aggressively every 3-4 days.